Revelation Biosciences, Inc., (REVB) News

Revelation Biosciences, Inc., (REVB): $1.83

0.08 (-4.19%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

D

Add REVB to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#272 of 357

in industry

Filter REVB News Items

REVB News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest REVB News From Around the Web

Below are the latest news stories about REVELATION BIOSCIENCES INC that investors may wish to consider to help them evaluate REVB as an investment opportunity.

REVB Releases Earnings and Prepares for Trials

By Brad Sorensen, CFA NASDAQ:REVB READ THE FULL REVB RESEARCH REPORT Revelation Biosciences (NASDAQ:REVB) is a life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. Revelation has multiple product candidates in development that we believe have promising potential and are based on the biology of phosphorylated hexaacyl

Yahoo | November 14, 2023

Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2023

SAN DIEGO, November 13, 2023--Revelation Biosciences, Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, today reported its three and nine months ended September 30, 2023 financial results.

Yahoo | November 13, 2023

Gemini Induces Pharmacologic Activity and Related Physiologic Changes in Multiple Preclinical Studies

SAN DIEGO, October 12, 2023--Revelation Biosciences Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), announced today that data from recent preclinical studies of the Company’s Gemini formulation demonstrated its therapeutic potential as a preventative therapy across multiple indications including infection and acute kidney injury. Data, discussed below, highlights the significant pharmacologic activity following administration of Gemini in healthy animals. Additional nonclinical biomarker an

Yahoo | October 12, 2023

Revelation Biosciences, Inc. to Present at the 2023 ROTH Healthcare Opportunities Conference

SAN DIEGO, October 04, 2023--Revelation Biosciences Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, today announced that its Chief Executive Officer James Rolke will be presenting at the upcoming 2023 ROTH Healthcare Opportunities Conference being held in New York, NY on October 12, 2023. Mr. Rolke will also be participating in one-on-one investor meetings at the

Yahoo | October 4, 2023

Revelation Biosciences Inc. Announces Appointment of Lakhmir Chawla, M.D. to Board of Directors

SAN DIEGO, October 02, 2023--Revelation Biosciences Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a life sciences company that is focused on the development of immunologic based therapies for the prevention and treatment of disease, today announced the appointment of Lakhmir Chawla M.D. to the Company’s Board of Directors (Board).

Yahoo | October 2, 2023

REVB Reports Solid Balance Sheet and Remains on Track

By Brad Sorensen, CFA NASDAQ:REVB READ THE FULL REVB RESEARCH REPORT Revelation Biosciences (NASDAQ:REVB) is a life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. Revelation has multiple product candidates in development that we believe have promising potential and are based on the biology of phosphorylated hexaacyl

Yahoo | August 14, 2023

Revelation Biosciences Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2023

SAN DIEGO, August 11, 2023--Revelation Biosciences Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a life sciences company that is focused on the development of immunologic based therapies for the prevention and treatment of disease, today reported its three and six months ended June 30, 2023 financial results.

Yahoo | August 11, 2023

REMINDER: Revelation Biosciences, Inc. Urges All Stockholders to Vote at the 2023 Annual Meeting of Stockholders

SAN DIEGO, June 29, 2023--Revelation Biosciences Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a life sciences company that is focused on the development of immunologic based therapies for the prevention and treatment of disease, today reminded stockholders that the virtual Annual Meeting of Stockholders (the "Annual Meeting") is scheduled for Friday, July 7, 2023, at 1:00 p.m. Eastern Time and urges all stockholders to vote now.

Yahoo | June 29, 2023

REVB: REVB Looks Attractive Ahead of Trials

By Brad Sorensen, CFA NASDAQ:REVB READ THE FULL REVB RESEARCH REPORT Revelation Biosciences (NASDAQ:REVB) is a life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. Revelation has multiple product candidates in development that we believe have promising potential and are based on the biology of phosphorylated hexaacyl

Yahoo | June 22, 2023

Revelation Biosciences Inc. Announces Adjournment of 2023 Annual Meeting of Stockholders to July 7, 2023 and Additional Proposal

SAN DIEGO, June 12, 2023--Revelation Biosciences Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a life sciences company that is focused on the development of immunologic based therapies for the prevention and treatment of disease, today announced that the Company has adjourned its 2023 Annual Meeting of Stockholders (the "Annual Meeting") originally scheduled to be held on June 9, 2023, to July 7, 2023, at 1:00 p.m., Eastern Time, or at such other time or such other date to which the meeti

Yahoo | June 12, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!